Winton Group’s Cogent Biosciences COGT Stock Holding History

Winton Group’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-14,382	Closed	-$511K	–	1152
2025 Q4	$511K	Buy	+14,382	New	+$404K	0.02%	631

Other funds holding COGT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Winton Group's COGT Position: Q1 2026 in Review

Winton Group sold out of Cogent Biosciences (COGT) in Q1 2026, closing a stake of 14,382 shares — an estimated $511K sold.

Winton Group first reported a position in COGT in Q4 2025 and held it in 1 quarter. The position peaked at $511K in Q4 2025. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

Winton Group reported no remaining Cogent Biosciences position as of Q1 2026 after selling out during the quarter.
Winton Group sold 14,382 Cogent Biosciences shares in Q1 2026, an estimated $511K.
Winton Group first reported a position in Cogent Biosciences in Q4 2025 and held it in 1 quarter.
Winton Group's Cogent Biosciences position peaked at $511K in Q4 2025.
305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on Winton Group's 13F filing for Q1 2026, filed 12 May 2026.